PELL Bio-Med Technology Co. Ltd. (6949.TW)

TWD 117.0

(0.86%)

EBITDA Summary of PELL Bio-Med Technology Co. Ltd.

  • PELL Bio-Med Technology Co. Ltd.'s latest annual EBITDA in 2023 was -353.17 Million TWD , down -78.3% from previous year.
  • PELL Bio-Med Technology Co. Ltd.'s latest quarterly EBITDA in 2024 Q1 was -77.18 Million TWD , up 15.51% from previous quarter.
  • PELL Bio-Med Technology Co. Ltd. reported an annual EBITDA of -198.87 Million TWD in 2022, down -23.68% from previous year.
  • PELL Bio-Med Technology Co. Ltd. reported an annual EBITDA of -157.29 Million TWD in 2021, down 0.0% from previous year.
  • PELL Bio-Med Technology Co. Ltd. reported a quarterly EBITDA of -77.18 Million TWD for 2024 Q1, up 15.51% from previous quarter.
  • PELL Bio-Med Technology Co. Ltd. reported a quarterly EBITDA of -118.39 Million TWD for 2023 Q3, down -2.84% from previous quarter.

Annual EBITDA Chart of PELL Bio-Med Technology Co. Ltd. (2023 - 2021)

Historical Annual EBITDA of PELL Bio-Med Technology Co. Ltd. (2023 - 2021)

Year EBITDA EBITDA Growth
2023 -353.17 Million TWD -78.3%
2022 -198.87 Million TWD -23.68%
2021 -157.29 Million TWD 0.0%

Peer EBITDA Comparison of PELL Bio-Med Technology Co. Ltd.

Name EBITDA EBITDA Difference
Apex Biotechnology Corp. 221.06 Million TWD 259.766%
Sinphar Pharmaceutical Co.,Ltd. 582.94 Million TWD 160.585%
Panion & Bf Biotech Inc. 327.21 Million TWD 207.933%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. 473.81 Million TWD 174.539%
GenMont Biotech Incorporation 71.76 Million TWD 592.111%
Abnova (Taiwan) Corporation 81.2 Million TWD 534.9%
Adimmune Corporation -512.42 Million TWD 31.078%
Tanvex BioPharma, Inc. -1.75 Billion TWD 79.87%
Polaris Group -1.38 Billion TWD 74.582%
Energenesis Biomedical CO.,LTD. -244.57 Million TWD -44.404%
UnicoCell Biomed Co., Ltd. -56.27 Million TWD -527.582%